Rémy Cointreau Q4 organic sales jump 8.9% as cognac demand recovers in China

Rémy Cointreau reported full-year revenue of €935.3 million, missing consensus of about €938 million, while reported sales fell 5.0% due largely to a 5.2% currency headwind. Fourth-quarter organic sales accelerated 8.9%, led by cognac growth of 15.5% organically, but full-year organic growth was only 0.2% and the company kept its current operating profit outlook for a low-double-digit to mid-teens organic decline. The update is mixed overall: improving quarterly momentum, but continued pressure from FX, China, and weaker full-year performance.

Analysis

The key signal is not the near-term print, but the dispersion inside the portfolio: the recovery is being led by higher-quality China/APAC cognac demand and travel retail, while the weak spots are still the U.S. base effect and partner brands. That mix matters because it implies management is gaining more from mix than from broad category recovery, which tends to produce better margin leverage than the headline sales trajectory suggests. However, the same FX that is flattering reported weakness can also conceal how fragile full-year earnings power remains if the dollar and renminbi stay volatile.

The market’s likely mistake is treating the quarter as a clean inflection rather than a reset of expectations. Confirmation of operating-profit guidance with a negative currency drag means the upside case is now heavily dependent on China stabilization and sustained replenishment in travel retail over the next 2-3 quarters, not just a single favorable comparison. If either channel stalls, the stock can de-rate quickly because the residual growth engine is concentrated and not yet broad-based.

Second-order, this is a read-through for premium spirits peers and distributors: names with more U.S.-exposed premium portfolio mix should screen better than those relying on China cognac or weaker partner-brand exposure. The contrarian view is that the stock may be less expensive than the headline miss implies if the market is discounting a permanently impaired China demand profile; if China continues to normalize and the U.S. de-stocks are nearing completion, the next 6 months could show operating leverage faster than consensus expects. Still, the asymmetry is limited until the company proves that the current quarter is repeatable rather than seasonal noise.

Key Decisions for Investors

• Long RCO.PA on weakness for a 3-6 month tactical trade: the setup favors mean reversion if China/travel retail remain stable, but size modestly because the recovery is still concentrated and FX can mask momentum.
• Pair trade: long a diversified premium spirits name with stronger U.S./category breadth vs short RCO.PA into earnings season. The relative value thesis is that broader exposure should carry a higher multiple if China recovery remains uneven.
• Sell upside calls or run a covered-call overlay on any rally in RCO.PA over the next 1-2 months. The guidance confirmation caps near-term upside unless the market starts pricing a durable China re-acceleration.
• Watch for a better entry after the next quarter if organic growth remains mid-to-high single digit in APAC but operating profit guidance is unchanged. That would likely create a better risk/reward than buying into the first bounce.